 |
GlaxoSmithKline's
experimental Ebola vaccine could be tested on patients in clinical safety
trials in the US as soon as next week, as the death toll from the deadly virus
continues to rise in west Africa.
Britain's
largest drug-maker is developing the vaccine with the Vaccine Research Centre
of the National Institutes of Health (NIH) in the US. Phase-I trials have
received the green light from the US health watchdog, the Food and Drug
Administration, Bloomberg reported. This is the first test in humans to assess
safety and efficacy – whether the drug works in a similar way to how it does in
animals.
The Ebola
outbreak has killed more than 1,400 people.
Michael
Kurilla, director of the Office of Biodefence, Research Resources and
Translational Research, told Bloomberg that health authorities are debating
whether to give the vaccine to people in west Africa at risk of catching the
virus, for which there is no cure. But he added that researchers may need to
assess the effect of the vaccine on humans for about a month. The NIH director,
Francis Collins, is scheduled to speak on Thursday about the agency's work on
Ebola vaccines.
A US
drug-maker, NewLink Genetics, based in Iowa, is also working on an Ebola
vaccine and has just struck a deal with another firm to manufacture the product
and increase its supply, before starting preclinical trials.
Experimental
Ebola treatments include ZMapp, made by San Diego-based Mapp Biopharmaceutical.
The drug has been given to Will Pooley, the British nurse who contracted the
virus in Sierra Leone and has been flown back to London.
Source: Guardians
No comments:
Post a Comment
Have your say, post your comments»»»
For more updates»»»Mail us: 9jawedey@gmail.com